Navigation Links
Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
Date:11/6/2008

BGC 945 Builds Upon a Proven Class of Drugs With Greater Tumor Selectivity

EMERYVILLE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has in-licensed a novel targeted oncology compound, BGC 945, from BTG International Limited based in the United Kingdom. Under the terms of the agreement, Onyx will obtain a worldwide license for BGC 945 and all of its related patents. Onyx will receive exclusive worldwide marketing rights and will be responsible for all product development and commercialization activities. BTG will receive a $13 million upfront payment, and payments of up to $72 million upon the attainment of certain global development and regulatory milestones, plus additional milestone payments upon the achievement of certain marketing approvals and commercial milestones. BTG will also receive royalties on future product sales.

"In-licensing a promising compound, such as BGC 945, with potential application in several large tumor markets strategically strengthens Onyx's pipeline and expands our portfolio as a growing biopharmaceutical company," said Tony Coles, M.D., president and chief executive officer of Onyx. "With proven success in developing and commercializing Nexavar as one of the leading targeted oncology therapies, we are well positioned to maximize BGC 945's full potential in a variety of tumors."

BGC 945 (ONX 0801) is designed to work by combining two proven approaches to improving outcomes for cancer patients. These include receptor-mediated targeting of tumor cells and inhibition of thymidylate synthase, a key enzyme involved in cell growth and division. BGC 945 (ONX 0801) targets malignant cells that overexpress the alpha-folate receptor, which is
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Memory Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
2. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
3. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
4. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
6. Onyx Pharmaceuticals to Present at the 2008 Credit Suisse Health Care Conference
7. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
9. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
10. Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
11. VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... (PRWEB) September 12, 2014 Advancing ... and decontamination of chemical and biological threats is ... by Worcester Polytechnic Institute (WPI) and the Georgian ... the Science for Peace and Security Programme of ... of NATO’s Advanced Research Workshop series, the event ...
(Date:9/12/2014)... (PRWEB) September 12, 2014 Today, “The ... on Indiegogo. , The film, directed by former ... Aldrin, Shimon Peres, Ashton Kutcher, Will.i.Am, Michio Kaku, and ... and there’s only one university in the world devoted ... change the lives of a billion people: Singularity University. ...
(Date:9/12/2014)... 2014 Sandia Biotech, Inc. announced today ... with STC.UNM (STC) for a technology developed by researchers ... New Mexico, and Queen Mary University of London in ... Recombinant Fluorescent Antibody Technology Platform (RFAP) was developed by ... and Dr. Angray Kang from Queen Mary’s Department of ...
(Date:9/11/2014)... (hiPSCs), researchers have gained new insight into what ... of neuronal signaling associated with this disease. They ... hiPSCs of healthy individuals and of patients with ... cells to release neurotransmitters, such as dopamine, that ... to various disorders. By discovering a simple method ...
Breaking Biology Technology:Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Documentary Film that Follows Singularity University Students as They Change the World Launches its IndieGoGo Fundraising Campaign 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 4Stem cells help researchers understand how schizophrenic brains function 2
... 16 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... of the company,s HIV tropism assay were presented ... Drug Resistance Workshop,in Sitges, Spain. Trofile was introduced ... in class CCR5 antagonist, in,August 2007. Recent enhancements ...
... /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc.,(TSX: PLI) ... compound in clinical trial in patients with ... the European Hematology Association,held in Copenhagen, Denmark ... Director R&D, Biology, presented data on,PBI-1402 in ...
... Inc. (Nasdaq: ALXN ) today announced that ... of Alexion,Pharmaceuticals, will present at the William Blair ... a.m., local time (10:10 a.m., eastern) on,Thursday, June ... Sinha,s remarks will be available live. You can,access ...
Cached Biology Technology:Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 2Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 3Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 4Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 5Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 6Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 2Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 3
(Date:9/12/2014)... attack from a pathogen, they sometimes respond by killing ... committing "cell suicide" to thwart further damage from the ... microscopic, spots or lesions on the plant. , But ... the plant regulates this "spotty" defense mechanism because the ... North Carolina State University have identified a number of ...
(Date:9/12/2014)... of dendritic cells in human skin have assorted functions ... report researchers in the journal EMBO Molecular Medicine ... the composition of dendritic cells in psoriatic skin lesions ... the disease. , "We urgently need new ways ... to patients and reduce the incidence of known side ...
(Date:9/11/2014)... Northumberland and Durham" by Nathaniel John Winch is re-published ... an example of combining modern information technology together with ... and data re-use. This publication will be supporting ongoing ... be seen as a model for other regions in ... the meticulous detail of old books with the interconnectedness ...
Breaking Biology News(10 mins):Corn spots: Study finds important genes in defense response 2Dendritic cells affect onset and progress of psoriasis 2Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 2Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 3
... ecosystem below an Antarctic glacier and learned that it survived ... growth. Described in the April 17 issue of ... a pool of brine trapped below Taylor Glacier and next ... Priscu , co-author of the Science article. Priscu ...
... over, Y chromosome it,s time X got some ... chromosome associated with being female, University of California, Berkeley, ... history of the X chromosome is every bit as ... important clues to the origins and benefits of sexual ...
... Sven Enerbck, Professor at the Institute of Biomedicine at the ... scientists who published their results in The New England ... Enerbck and others show that adults use brown fat to ... new possibilities in treating overweight and obesity. It has ...
Cached Biology News:Ancient ecosystem thrives millions of years below Antarctic glacier 2The story of X -- evolution of a sex chromosome 2The story of X -- evolution of a sex chromosome 3The story of X -- evolution of a sex chromosome 4
...
... Lyophilized. Lyophilized from 2 mM sodium ... human liver. Cathepsin D is a major ... as a 52 kDa proenzyme. Overexpression of ... associated with higher risk of relapse and ...
... Grade Thrombin is a highly purified preparation ... with appropriate vectors. The preparation is functionally ... is free of detectable contaminating proteases. Prepared ... by certified tests to be negative for ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
Biology Products: